Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux

Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic
Pharmaceuticals Company Tubilux

ROCHESTER, N.Y., Oct. 5 /PRNewswire/ -- Bausch & Lomb, the global eye health
company, today announced it has acquired the commercial assets of Tubilux
Pharma S.p.A.

Tubilux is a privately held ophthalmic pharmaceuticals company that develops
and markets a range of proprietary, over-the-counter, and branded generic
products primarily in Italy, and with distribution in approximately 30 other
countries.

Under the terms of the agreement, Bausch & Lomb has acquired the company's
ophthalmic pharmaceuticals portfolio, as well as its commercial and sales
operations. Group Tubilux will retain its manufacturing operation, producing
existing products for Bausch & Lomb under a multi-year contract.

"This agreement more than doubles our presence in the Italian ophthalmic
pharmaceuticals market," said Charl van Zyl, head of Bausch & Lomb's
Pharmaceuticals business for Europe, Middle East and Africa. "Bausch & Lomb is
committed to expanding our portfolio offerings, and we believe that this
investment will prove successful for the company, doctors and patients alike."

The acquired Tubilux portfolio includes products for dry eye relief (Oxyal,
Lipimix, and Vitadrop); for glaucoma (Cebrolux and Timolux); for
anti-infective use (Oftaquix); and for anti-inflammatory use (Fluaton).

"As a result of this transaction, Tubilux will strengthen its focus and
presence in the ophthalmic pharmaceutical contract manufacturing sector,
including ointments, gels and eye drop formats," said Emidio Fedeli, chief
executive officer of Group Tubilux.

Sal Oppenheim Jr. & Cie. KGaA Milan Branch acted as the sole financial advisor
of Group Tubilux in this transaction.

Financial terms of the agreement will not be made public.

About Bausch & Lomb
Bausch & Lomb is dedicated to bringing visionary ideas to eye health. Its core
businesses include contact lenses and lens care products, ophthalmic surgical
devices and instruments, and ophthalmic pharmaceuticals. The Bausch & Lomb
name is one of the best-known and most respected healthcare brands in the
world. Founded in 1853, the company is headquartered in Rochester, N.Y., and
employs more than 10,000 people worldwide. Its products are available in more
than 100 countries. More information is available at www.bausch.com.

SOURCE Bausch & Lomb

Mike McDougall, APR, Vice President, Corporate Communications and Public
Affairs, Bausch & Lomb, +1-585-338-5469 or mmcdougall@bausch.com; or Luigi
Baiocchi, Human Resources Director, Tubilux , +39 06911831 or
baiocchi@tubilux.it